The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy ... find a more powerful competitor to Lilly's Zepbound, also known as Mounjaro.

CNBC Select evaluated dozens of auto loan lenders based on their rates and terms, selection of loan options, car-buying experience and other factors. Below are our picks for the best auto loan ...

Wegovy (semaglutide) has a list price of $1,349.02 for a four-week supply. Competitor Zepbound (tirzepatide) is a smidge cheaper at $1,086.37. And as these drugs are FDA-approved for chronic ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Right now, Novo Nordisk and Eli Lilly are the biggest players in town when it comes to treating diabetes and obesity. Viking Therapeutics has a unique candidate in its pipeline that could disrupt ...

This is particularly interesting because mainstream obesity drugs such as Wegovy and Zepbound are administered via injection. An oral tablet could open up new doors for patients who seeking ...